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Allergic rhinitis (AR) is increasing in prevalence and
becoming more difficult to treat. There is a subset of
patients who are refractory to ARIA-defined rhinitis
management approaches [1]. Even though new treat-
ments have been made available for symptomatic relief,
no new class of medication was forthcoming, until
recently. The situation has now changed. MP29-02* is a
novel intranasal formulation of azelastine hydrochloride
(AZE) and fluticasone propionate (FP) in an advanced
delivery system. It benefits from antihistamine, mast-cell
stabilizing, anti-leukotriene and anti-inflammatory prop-
erties, made up in a unique formulation and delivered
using an improved device (vs marketed intranasal ster-
oid sprays (INS)). MP29-02*’s novel formulation and
spray characteristics (e.g. finer droplet size, consistent
spray release, wider spray angle) were developed to
improve drug deposition on the nasal mucosa and
ensure optimal retention. The impact has been observed
both pharmacokinetically, [2] and clinically [3,4]. MP29-
02* was created to be more effective than any existing
symptomatic treatment for AR, have a rapid onset of
action and a sustained effect. Delivered as a single spray
from one device, the aim was to improve compliance,
maximize convenience for patients and simplify dosing.
This product provides more effective relief than cur-
rently considered gold standard treatment, INS. A
recent publication by Meltzer et al, 4 re-assessed the
efficacy of MP29-02* versus AZE and FP in an innova-
tive and clinically relevant way by responder analyses.
The authors determined different response cut-offs from
30 to 90% reflective total nasal symptom score (rTNSS)
reduction from baseline. More MP29-02* patients
achieved each response (vs FP or AZE), and days earlier.
A response ceiling of ≥60% was identified above which
INS failed to differentiate from placebo. This may
explain why moderate/severe AR patients still complain
of bothersome symptoms despite ARIA-guided treat-
ment. Patients who remain symptomatic on monotherapy
should experience a significant reduction in their symp-
toms with MP29-02*, exceeding that which they have
experienced in the past, and many days faster than an
INS. MP29-02* comprises all the pharmacological princi-
ples foreseen in the ARIA treatment algorithm.
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